GenScript Launches TurboCHO Protein Kit
Analysis based on 8 articles · First reported May 12, 2026 · Last updated May 12, 2026
The launch of the TurboCHO Protein Expression Kit by GenScript Biotech Corporation is expected to positively impact the biotechnology and pharmaceutical markets by accelerating drug discovery and biologics development. This innovation could lead to faster candidate selection and reduced time-to-data for research teams, potentially increasing efficiency across the industry.
GenScript Biotech Corporation launched its TurboCHO Protein Expression Kit, a next-generation antibody expression reagent, at the PEGS Summit in Boston on May 12, 2026. This kit is designed to significantly reduce the time required to produce research-grade antibodies and proteins, enabling labs to generate high-quality protein in as little as five business days. Sherry Shao, GenScript Biotech Corporation's Rotating CEO, and Ray Chen, President of GenScript Biotech Corporation Life Science Group, emphasized the kit's role in eliminating critical bottlenecks in drug discovery, improving cost efficiency, and accelerating the development of new medicines. The product is available in 'Pro' and 'Prime' configurations, with the 'Prime' version offering even faster results. This launch is the first phase of GenScript Biotech Corporation's broader innovation roadmap aimed at driving industry leadership.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard